Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multicentric, Post-Marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants

Trial Profile

An Open, Multicentric, Post-Marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 16 Oct 2008 Actual start date changed from Jul 2004 to Nov 2004 as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Actual patient number (2590) added as reported by ClinicalTrials.gov.
    • 22 Aug 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top